-
Something wrong with this record ?
Pharmacological inhibition of eIF2alpha phosphorylation by integrated stress response inhibitor (ISRIB) ameliorates vascular calcification in rats
J. Dong, S. Jin, J. Guo, R. Yang, D. Tian, H. Xue, L. Xiao, Q. Guo, R. Wang, M. Xu, X. Teng, Y. Wu
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
PubMed Central
from 2020
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Aorta metabolism MeSH
- Cholecalciferol metabolism MeSH
- Eukaryotic Initiation Factor-2 * MeSH
- Phosphorylation MeSH
- Rats MeSH
- Vascular Calcification * chemically induced drug therapy prevention & control MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
Vascular calcification (VC) is an independent risk factor for cardiovascular events and all-cause mortality with the absence of current treatment. This study aimed to investigate whether eIF2alpha phosphorylation inhibition could ameliorate VC. VC in rats was induced by administration of vitamin D3 (3×10(5) IU/kg, intramuscularly) plus nicotine (25 mg/kg, intragastrically). ISRIB (0.25 mg/kg·week), an inhibitor of eIF2alpha phosphorylation, ameliorated the elevation of calcium deposition and ALP activity in calcified rat aortas, accompanied by amelioration of increased SBP, PP, and PWV. The decreased protein levels of calponin and SM22alpha, and the increased levels of RUNX2 and BMP2 in calcified aorta were all rescued by ISRIB, while the increased levels of the GRP78, GRP94, and C/EBP homologous proteins in rats with VC were also attenuated. Moreover, ISRIB could prevent the elevation of eIF2alpha phosphorylation and ATF4, and partially inhibit PERK phosphorylation in the calcified aorta. These results suggested that an eIF2alpha phosphorylation inhibitor could ameliorate VC pathogenesis by blocking eIF2alpha/ATF4 signaling, which may provide a new target for VC prevention and treatment.
Department of Physiology Hebei Medical University Shijiazhuang China
Hebei Collaborative Innovation Center for Cardio Cerebrovascular Disease Shijiazhuang China
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22021455
- 003
- CZ-PrNML
- 005
- 20230516114855.0
- 007
- ta
- 008
- 220907s2022 xr ad f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.934797 $2 doi
- 035 __
- $a (PubMed)35616039
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Dong, Jianlong $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 245 10
- $a Pharmacological inhibition of eIF2alpha phosphorylation by integrated stress response inhibitor (ISRIB) ameliorates vascular calcification in rats / $c J. Dong, S. Jin, J. Guo, R. Yang, D. Tian, H. Xue, L. Xiao, Q. Guo, R. Wang, M. Xu, X. Teng, Y. Wu
- 520 9_
- $a Vascular calcification (VC) is an independent risk factor for cardiovascular events and all-cause mortality with the absence of current treatment. This study aimed to investigate whether eIF2alpha phosphorylation inhibition could ameliorate VC. VC in rats was induced by administration of vitamin D3 (3×10(5) IU/kg, intramuscularly) plus nicotine (25 mg/kg, intragastrically). ISRIB (0.25 mg/kg·week), an inhibitor of eIF2alpha phosphorylation, ameliorated the elevation of calcium deposition and ALP activity in calcified rat aortas, accompanied by amelioration of increased SBP, PP, and PWV. The decreased protein levels of calponin and SM22alpha, and the increased levels of RUNX2 and BMP2 in calcified aorta were all rescued by ISRIB, while the increased levels of the GRP78, GRP94, and C/EBP homologous proteins in rats with VC were also attenuated. Moreover, ISRIB could prevent the elevation of eIF2alpha phosphorylation and ATF4, and partially inhibit PERK phosphorylation in the calcified aorta. These results suggested that an eIF2alpha phosphorylation inhibitor could ameliorate VC pathogenesis by blocking eIF2alpha/ATF4 signaling, which may provide a new target for VC prevention and treatment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a aorta $x metabolismus $7 D001011
- 650 _2
- $a cholekalciferol $x metabolismus $7 D002762
- 650 12
- $a eukaryotický iniciační faktor 2 $7 D015852
- 650 _2
- $a fosforylace $7 D010766
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 12
- $a vaskulární kalcifikace $x chemicky indukované $x farmakoterapie $x prevence a kontrola $7 D061205
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Jin, Sheng $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China
- 700 1_
- $a Guo, Jingjing $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Yang, Rui $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Tian, Danyang $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Xue, Hongmei $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Xiao, Lin $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Guo, Qi $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Wang, Ru $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Xu, Meng $u Department of Physiology, Hebei Medical University, Shijiazhuang, China
- 700 1_
- $a Teng, Xu $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Key Laboratory of Neurophysiology, Shijiazhuang, China
- 700 1_
- $a Wu, Yuming $u Department of Physiology, Hebei Medical University, Shijiazhuang, China $u Hebei Collaborative Innovation Center for Cardio-Cerebrovascular Disease, Shijiazhuang, China $u Hebei Key Laboratory of Neurophysiology, Shijiazhuang, China
- 773 0_
- $w MED00003824 $t Physiological research $x 1802-9973 $g Roč. 71, č. 3 (2022), s. 379-388
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35616039 $y Pubmed
- 910 __
- $a ABA008 $b A 4120 $c 266 $y p $z 0
- 990 __
- $a 20220907 $b ABA008
- 991 __
- $a 20230516114852 $b ABA008
- 999 __
- $a ok $b bmc $g 1851685 $s 1172723
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 71 $c 3 $d 379-388 $e 20220526 $i 1802-9973 $m Physiological research $n Physiol. Res. (Print) $x MED00003824
- LZP __
- $b NLK198 $a Pubmed-20220907